Aureobasidin A is an orally active cyclic peptide antibiotic[1]. Aureobasidin A is an inhibitor of inositol phosphorylating ceramide synthase AUR1[2]. Aureobasidin A has antifungal and antiparasitic activities[3, 4].
In vitro, Aureobasidin A (20ng/mL) treatment of Candida albicans SC5314 for 24h completely inhibited the growth of the strain[5]. Aureobasidin A (5, 10μg/mL) treated with Toxoplasma gondii tachyzoites for 24h significantly inhibited the proliferation of Toxoplasma gondii tachyzoites[6].
In vivo, Aureobasidin A (20, 40mg/kg) was used orally and subcutaneously to treat mice with systemic Candida infection, producing good therapeutic effects, which were superior to fluconazole and amphotericin B[7].
References:
[1] Teymuri M, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans[J]. Bioorganic & Medicinal Chemistry Letters, 2021, 41: 128013.
[2] Katsuki Y, Yamaguchi Y, Tani M. Overexpression of PDR16 confers resistance to complex sphingolipid biosynthesis inhibitor aureobasidin A in yeast Saccharomyces cerevisiae[J]. FEMS microbiology letters, 2018, 365(3): fnx255.
[3] Alimehr S, Shams-Ghahfarokhi M, Razzaghi Abyaneh M. Antifungal activity of Aureobasidin a in combination with Fluconazole against fluconazole-resistant Candida albicans[J]. Infection Epidemiology and Microbiology, 2020, 6(4): 285-291.
[4] Tanaka A K, Valero V B, Takahashi H K, et al. Inhibition of Leishmania (Leishmania) amazonensis growth and infectivity by aureobasidin A[J]. Journal of Antimicrobial Chemotherapy, 2007, 59(3): 487-492.
[5] Zheng L, Xu Y, Dong Y, et al. Chromosome 1 trisomy confers resistance to aureobasidin A in Candida albicans[J]. Frontiers in Microbiology, 2023, 14: 1128160.
[6] Alqaisi A Q I, Mbekeani A J, Llorens M B, et al. The antifungal Aureobasidin A and an analogue are active against the protozoan parasite Toxoplasma gondii but do not inhibit sphingolipid biosynthesis[J]. Parasitology, 2018, 145(2): 148-155.
[7] TAKESAKO K, KURODA H, INOUE T, et al. Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic[J]. The Journal of antibiotics, 1993, 46(9): 1414-1420.
Aureobasidin A是一种具有口服活性的环状肽抗生素[1]。Aureobasidin A是肌醇磷酸化神经酰胺合成酶 AUR1的抑制剂[2]。Aureobasidin A有抗真菌和抗寄生虫活性[3, 4]。
在体外,Aureobasidin A(20ng/mL)处理白色念珠菌SC5314 24h,完全抑制了菌株的生长[5]。Aureobasidin A(5, 10μg/mL)处理弓形虫速殖子24h,显著抑制了弓形虫速殖子的增殖[6]。
在体内,Aureobasidin A(20, 40mg/kg)通过口服和皮下治疗全身念珠菌感染的小鼠,产生了良好的治疗效果,作用优于氟康唑和两性霉素B[7]。
















